Source: https://www.law.cornell.edu/cfr/text/21/part-314/subpart-H
Timestamp: 2016-08-31 06:18:33
Document Index: 14350924

Matched Legal Cases: ['art 314', 'art 314', 'art 314', 'art 314', '§ 314', '§ 314', '§ 314', '§ 314', '§ 314', '§ 314', '§ 314', 'art 314']

21 CFR Part 314, Subpart H - Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses | US Law | LII / Legal Information Institute
CFR › Title 21 › Chapter I › Subchapter D › Part 314 › Subpart H 21 CFR Part 314, Subpart H - Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses
There are 3 Updates appearing in the Federal Register for 21 CFR Part 314. View below or at eCFR (GPOAccess)
§ 314.500 — Scope.
§ 314.510 — Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity.
§ 314.520 — Approval with restrictions to assure safe use.
§ 314.530 — Withdrawal procedures.
§ 314.540 — Postmarketing safety reporting.
§ 314.550 — Promotional materials.
§ 314.560 — Termination of requirements.
57 FR 58958, Dec. 11, 1992, unless otherwise noted.
Title 21 published on 2015-04-01.The following are only the Rules published in the Federal Register after the published date of Title 21.For a complete list of all Rules, Proposed Rules, and Notices view the Rulemaking tab.2015-07-08; vol. 80 # 130 - Wednesday, July 8, 201580 FR 38915 - Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products
Title 21 published on 2015-04-01The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 21 CFR Part 314 after this date.2015-07-08; vol. 80 # 130 - Wednesday, July 8, 201580 FR 38915 - Permanent Discontinuance or Interruption in Manufacturing of Certain Drug or Biological Products